Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent Ganglioside Vaccine in Metastatic Sarcoma
NCT01141491Phase 2Completed
- Sponsor
- MabVax Therapeutics
- Start
- Jun 2010
- Primary completion
- Sep 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trivalent ganglioside vaccine in sarcoma (2 arms), sponsored by MabVax Therapeutics. Primary endpoint: Progression Free Survival at 3 years. Started Jun 2010; status: completed.
02
Drugs
trivalent ganglioside vaccine
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT01141491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141491.